As Executive Chairman of Quanterix’s Board of Directors, Dr. Madaus brings more than 20 years of experience in the diagnostics and life science industries. He most recently served as President, Chairman and CEO of Millipore Corporation, recently acquired by Merck KGaA. Before joining Millipore, Dr. Madaus was President, CEO and head of North American Operations for Roche Diagnostics Corporation. Prior to this he served as Vice President of Business Development for Roche Molecular Diagnostics and General Manager of Boehringer Mannheim Canada. He also held a number of senior-level sales, marketing and product management positions with Boehringer Mannheim Corporation in both Germany and the US. Dr. Madaus is a director of the Massachusetts High Technology Council and serves on the Life Sciences Collaborative Leadership Council of the Massachusetts Technology Collaborative. He has a Doctor of Veterinary Medicine from the University of Munich, Germany and a Ph.D. in veterinary medicine from the Veterinary School of Hanover, Germany.

Dr. Cole is a General Partner at Flagship Ventures where he focuses on Life Science investments. Prior to Flagship, he served as Program Executive at Vertex Pharmaceuticals and as Medical Director at Cytotherapeutics. While at Flagship, he has led investments in Agios Pharmaceuticals, Tetraphase, Concert Pharmaceuticals, Ensemble Discovery, Alvine Pharmaceuticals, and CombinatoRx. Dr. Cole co-founded Ensemble Discovery and served as CEO of the company during its initial stages. In addition to Quanterix, he currently serves on the Board of Directors at Agios Pharmaceuticals, Tetraphase, Concert Pharmaceuticals, Ensemble Discovery, AVEO Pharmaceuticals, and CGI Pharmaceuticals, and is an Observer on the Board of Directors of Alvine. Dr. Cole obtained post-graduate training in medicine at the Johns Hopkins Hospital and in neurology at Massachusetts General Hospital. He holds an M.D. from the University of Pennsylvania School of Medicine and received an A.B. magna cum laude with High Distinction in English from Dartmouth College.

Mr. Crandell is a co-founder and Managing Director of ARCH Venture Partners where he focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, telecommunications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory. In addition to Quanterix, Mr. Crandell has played key roles in the formation and initial funding rounds at AlfaLight, ALIS, Eichrom Industries, Nanophase Technologies and Illinois Superconductor. He was also responsible for ARCH’s investment in New Era of Networks, Apropos Technology, Teach.com, CelebrateExpress, Ahura Scientific, Adesto Technologies, and Crystal IS, among others. In addition to Quanterix, Mr. Crandell is a director of Nanosys, AlfaLight, Adesto Technologies, CelebrateExpress, Crystal IS and also serves as a Director of the Illinois Venture Capital Association and the National Venture Capital Association. He holds an M.B.A. from The University of Chicago, an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

Mr. Nahirny is a Managing Director and a founding Partner of Bain Capital Ventures and a Managing Director of the firm. Prior to joining Bain, Mr. Nahirny was a Partner at McKinsey & Company where he worked closely with the senior management and Boards of his clients on a broad range of strategic and operations issues. He previously worked in the Mergers and Acquisitions Group of First Boston in both New York and Tokyo. In addition to Quanterix, Mr. Nahirny serves on the Boards of Imerica, Nanosphere, Servigistics and Tengion as well as Children’s Hospital Boston Board of Overseers, New England Venture Capital Association, and Yale Entrepreneurial Society. Mr. Nahirny received an M.B.A. with High Distinction from Harvard Business School, where he was a Baker Scholar, and a B.A. magna cum laude from Yale University.

David R. Walt is Robinson Professor of Chemistry at Tufts University and a Howard Hughes Medical Institute Professor. Dr. Walt is a member of the U.S. National Academy of Engineering, a fellow of the American Association for the Advancement of Science, and a fellow of the American Institute for Medical and Biological Engineering. Dr. Walt serves on the Editorial Advisory Board of several journals including Analytical Chemistry, Analytical and Bioanalytical Chemistry, Sensor Letters, and the Indian Journal of Biotechnology.He served as Executive Editor of Applied Biochemistry and Biotechnology and was a founding member of the Editorial Advisory Board for the Journal of Combinatorial Chemistry. Dr. Walt is the Scientific Founder and Chair of the Scientific Advisory Board at Quanterix, and a Director of Illumina. He has received numerous national and international awards and honors recognizing his work including a National Science Foundation Special Creativity Award, The Biosensors and Bioelectronics Award, and the Samuel R. Scholes Award in Glass Science. Dr. Walt has received the Tufts Outstanding Faculty Award twice in addition to the Distinguished Research Award. He has published over 200 papers, holds over 45 patents, and has given hundreds of invited lectures and scientific presentations. Dr. Walt received his Ph.D. in Chemical Biology from SUNY at Stony Brook and a B.S. in Chemistry from the University of Michigan.